Covance CVD

  1. All
  2. Commentary
  3. Headlines
    1. LabCorp Sees Strong 1Q and Growth in Covance Trials; We Plan Modest Boost to Fair Value Estimate

      Commentary

      Mon, 27 Apr 2015

      patient database to secure incremental projects for its Covance trial business, we have shifted our expectations for projected ..... prior-year period. We were surprised by the weakness in Covance 's central lab segment, which was largely fueled by lower-priced

    2. Quintiles-Quest Joint Venture Is Logical Response to LabCorp Competition; Maintaining Fair Values

      Commentary

      Tue, 31 Mar 2015

      recent $6 billion acquisition of Covance , an admittedly unorthodox pairing ..... patient database from LabCorp with Covance 's clinical trial business could ..... patient database to speed enrollment of Covance trials, the combined firm's progress

    3. Quintiles and Quest Pursue Joint Venture to Match LabCorp's Capabilities

      Commentary

      Tue, 31 Mar 2015

      recent $6 billion acquisition of Covance , an admittedly unorthodox pairing ..... patient database from LabCorp with Covance ’s clinical trials business could ..... database to quicken enrollment of Covance trials, the combined firm’s progress

    4. LabCorp Sees Early Benefits From Covance Deal

      Commentary

      Fri, 20 Feb 2015

      LabCorp finished off 2014 with strong performance in the fourth quarter, and our minor adjustments did not materially move the needle on our $127 fair value estimate. With year-over-year revenue growth hitting our estimates on the nose, LabCorp also managed to largely match our projections on the

    5. From Barron’s, January 26, 2015 (Part 1)

      Commentary

      Sat, 24 Jan 2015

      attention to Q4 earnings. There are significant execution risks in Lab Corp Am [ LH ] pending expensive acquisition of Covance [ CVD ]; S&P has downgraded the debt from BBB to BBB-. A turnaround of Urban Outfitters [ URBN ] is possible; Barron

    6. Strong Revenue Growth Continues at WuXi, but Margin Contraction Weighs on Earnings Growth

      Commentary

      Thu, 13 Nov 2014

      posted strong growth of 11%. This was well in excess of the 3%-7% growth posted by early-stage U.S. peers Covance and Charles River, although WuXi is growing off a much smaller base. Longer term, we expect the U.S. business to

    7. LabCorp Takeover Offers Attractive Price for Covance Shareholders

      Commentary

      Mon, 3 Nov 2014

      Covance announced that it has agreed to be acquired by LabCorp for a mixture of cash and stock equal to approximately $105 per Covance share. For Covance shareholders, we think LabCorp’s offer represents an attractive

    8. LabCorp Plans for Covance Acquisition; Our Fair Value Estimate Stands

      Commentary

      Mon, 3 Nov 2014

      announcement of its impending acquisition of Covance , we think investors may not fully ..... incorporating our assumptions about the Covance business and LabCorp's financing ..... raising our fair value estimate on Covance to the $105 offer price. We think

    9. Charles Rivers Posts Strong 2Q Results as Early Stage Demand Finally Returns

      Commentary

      Thu, 7 Aug 2014

      year. We believe this segment is the best comparison to Covance 's early-stage business, and Charles River’s performance compares favorably to Covance 's early-stage reported revenue of 7.7%. While Charles

    10. Quintiles Posts Solid 2Q, Weak Bookings Unlikely to Be a Cause for Concern

      Commentary

      Thu, 31 Jul 2014

      rather than a more concerning slowdown in demand. Based on the strong book/bill ratios we have seen out of its peers Covance and ICON, which have already reported this quarter, we are inclined to agree with management. The firm's less attractive

    « Prev12345Next »
    Content Partners